## Giuseppina Barrera

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6504880/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Peroxisome Proliferator-Activated Receptors (PPARs) and Oxidative Stress in Physiological Conditions and in Cancer. Antioxidants, 2021, 10, 1734.	2.2	24
2	Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies. Antioxidants, 2021, 10, 1942.	2.2	33
3	Novel tetrahydroacridine derivatives with iodobenzoic moieties induce GO/G1 cell cycle arrest and apoptosis in A549 non-small lung cancer and HT-29 colorectal cancer cells. Molecular and Cellular Biochemistry, 2019, 460, 123-150.	1.4	19
4	DNA damage by lipid peroxidation products: implications in cancer, inflammation and autoimmunity. AIMS Genetics, 2017, 04, 103-137.	1.9	105
5	Mitochondrial Dysfunction in Cancer and Neurodegenerative Diseases: Spotlight on Fatty Acid Oxidation and Lipoperoxidation Products. Antioxidants, 2016, 5, 7.	2.2	55
6	Generation of Adducts of 4-Hydroxy-2-nonenal with Heat Shock 60 kDa Protein 1 in Human Promyelocytic HL-60 and Monocytic THP-1 Cell Lines. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-13.	1.9	9
7	Role of 4-Hydroxynonenal-Protein Adducts in Human Diseases. Antioxidants and Redox Signaling, 2015, 22, 1681-1702.	2.5	92
8	Drug Delivery Nanoparticles in Skin Cancers. BioMed Research International, 2014, 2014, 1-13.	0.9	120
9	The inclusion complex of 4-hydroxynonenal with a polymeric derivative of β-cyclodextrin enhances the antitumoral efficacy of the aldehyde in several tumor cell lines and in a three-dimensional human melanoma model. Free Radical Biology and Medicine, 2013, 65, 765-777.	1.3	14
10	Interaction of aldehydes derived from lipid peroxidation and membrane proteins. Frontiers in Physiology, 2013, 4, 242.	1.3	254
11	AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells. PPAR Research, 2012, 2012, 1-16.	1.1	22
12	Oxidative Stress and Lipid Peroxidation Products in Cancer Progression and Therapy. ISRN Oncology, 2012, 2012, 1-21.	2.1	464
13	Rosiglitazone and AS601245 Decrease Cell Adhesion and Migration through Modulation of Specific Gene Expression in Human Colon Cancer Cells. PLoS ONE, 2012, 7, e40149.	1.1	27
14	Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. Free Radical Biology and Medicine, 2011, 50, 313-322.	1.3	49
15	Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells. Free Radical Biology and Medicine, 2011, 51, 1610-1618.	1.3	26
16	PPARÎ <sup>3</sup> ligands inhibit telomerase activity and hTERT expression through modulation of the Myc/Mad/Max network in colon cancer cells. Journal of Cellular and Molecular Medicine, 2010, 14, 1347-1357.	1.6	23
17	The "Two-Faced" Effects of Reactive Oxygen Species and the Lipid Peroxidation Product 4-Hydroxynonenal in the Hallmarks of Cancer. Cancers, 2010, 2, 338-363.	1.7	76
18	Exposure of HL-60 human leukaemic cells to 4-hydroxynonenal promotes the formation of adduct(s) with α-enolase devoid of plasminogen binding activity. Biochemical Journal, 2009, 422, 285-294.	1.7	22

**GIUSEPPINA BARRERA** 

#	Article	IF	CITATIONS
19	Lipid peroxidation: control of cell proliferation, cell differentiation and cell death. Molecular Aspects of Medicine, 2008, 29, 1-8.	2.7	121
20	The Role of PPAR Ligands in Controlling Growth-Related Gene Expression and their Interaction with Lipoperoxidation Products. PPAR Research, 2008, 2008, 1-15.	1.1	20
21	4-Hydroxynonenal and PPARÎ <sup>3</sup> ligands affect proliferation, differentiation, and apoptosis in colon cancer cells. Free Radical Biology and Medicine, 2007, 42, 1661-1670.	1.3	79
22	4-Hydroxynonenal inhibits telomerase activity and hTERT expression in human leukemic cell lines. Free Radical Biology and Medicine, 2006, 40, 1578-1591.	1.3	38
23	4â€Hydroxynonenal and cell cycle. BioFactors, 2005, 24, 151-157.	2.6	23
24	4-Hydroxynonenal modulation of p53 family gene expression in the SK-N-BE neuroblastoma cell line. Free Radical Biology and Medicine, 2005, 38, 215-225.	1.3	58
25	4-hydroxynonenal and regulation of cell cycle: effects on the pRb/E2F pathway. Free Radical Biology and Medicine, 2004, 37, 597-606.	1.3	62
26	Peroxisome Proliferator-Activated Receptor Ligands Affect Growth-Related Gene Expression in Human Leukemic Cells. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 932-942.	1.3	45
27	4-Hydroxynonenal affects pRb/E2F pathway in HL-60 human leukemic cells. Biochemical and Biophysical Research Communications, 2002, 295, 267-275.	1.0	30
28	Synergistic effect of 4-hydroxynonenal and PPAR ligands in controlling human leukemic cell growth and differentiation. Free Radical Biology and Medicine, 2002, 32, 233-245.	1.3	61
29	4-Hydroxynonenal-Induced MEL Cell Differentiation Involves PKC Activity Translocation. Biochemical and Biophysical Research Communications, 2000, 272, 75-80.	1.0	32
30	Inhibition of D1, D2, and a cyclin expression in HL-60 cells by the lipid peroxydation product 4-hydroxynonenal. Free Radical Biology and Medicine, 1999, 26, 1578-1586.	1.3	51
31	4-Hydroxynonenal As a Biological Signal: Molecular Basis and Pathophysiological Implications. Antioxidants and Redox Signaling, 1999, 1, 255-284.	2.5	237
32	4-Hydroxynonenal Specifically Inhibits c-myb but Does Not Affect c-fos Expressions in HL-60 Cells. Biochemical and Biophysical Research Communications, 1996, 227, 589-593.	1.0	39
33	Effect of 4-hydroxynonenal on cell cycle progression and expression of differentiation-associated antigens in HL-60 cells. Free Radical Biology and Medicine, 1996, 20, 455-462.	1.3	54
34	Induction of differentiation in human HL-60 cells by 4-hydroxynonenal, a product of lipid peroxidation. Experimental Cell Research, 1991, 197, 148-152.	1.2	94
35	Effect of 4-Hydroxynonenal on c-myc Expression. Toxicologic Pathology, 1987, 15, 238-240.	0.9	54